Genetic epidemiology of sepsis and septic shock

Seminars in Respiratory and Critical Care Medicine

Volumn 25, Issue 6, 2004, Pages 611-618

  Wood, Kelly A ^a   Angus, Derek C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Gene expression; Genetics; Genomics; Microarrays; Sepsis; Single nucleotide polymorphisms

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; ENVIRONMENTAL FACTOR; FEMALE; GENE FREQUENCY; GENETIC EPIDEMIOLOGY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDIATOR RELEASE; MORTALITY; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

EID: 11144306450     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-860977     Document Type: Review

References (43)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310
2. Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in eight academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA 1997;278:234-240
3. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995;273:117-123
4. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997;25:1095-1100
5. Esmon CT. Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood 2000;95:1113-1116
6. Matthay MA. Severe sepsis: a new treatment with both anticoagulant and antiinflammatory properties [editorial]. N Engl J Med 2001;344:759-762
7. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-871
8. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
9. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-1377
10. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988;318:727-732
11. Collins FS. Shattuck lecture: medical and societal consequences of the Human Genome Project. N Engl J Med 1999; 341:28-37
12. Nadel S, Newport MJ, Booy R, Levin M. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 1996;174:878-880
13. Fang XM, Schroder S, Hoeft A, Stuber F. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999;27: 1330-1334
14. Stuber F, Udalova IA, Book M, et al. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 1995; 46:42-50
15. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996;24:381-384
16. Mira JP, Cariou A, Grall F, et al. Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality. A multicenter study. JAMA 1999;282: 561-568
17. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420:885-891
18. Cobb JP, Laramie JM, Stormo GD, et al. Sepsis gene expression profiling: murine splenic compared with hepatic responses determined by using complementary DNA microarrays. Crit Care Med 2002;30:2711-2721
19. Samuel JE, Kiss K, Varghees S. Molecular pathogenesis of Coxiella burnetii in a genomics era. Ann N Y Acad Sci 2003; 990:653-663
20. Hopf HW. Molecular diagnostics of injury and repair responses in critical illness: what is the future of "monitoring" in the intensive care unit? Crit Care Med 2003;31:S518-S523
21. Stephens JC, Schneider JA, Tanguay DA, et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001;293:489-493
22. Kumar A, Short J, Parrillo JE. Genetic factors in septic shock. JAMA 1999;282:579-581
23. Kellum JA, Angus DC. Genetic variation and risk of sepsis. Minerva Anestesiol 2003;69:245-253
24. Lowe PR, Galley HF, Abdel-Fattah A, Webster NR. Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 2003;31:34-38
25. Gallagher PM, Lowe G, Fitzgerald T, et al. Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 2003;58:154-156
26. Wood KA Kellum JA, Ferrell R, et al. The IL-10 - 819T polymorphism is associated with increased susceptibility to severe sepsis [abstract]. Crit Care 2003;7(Suppl 2):S21
27. a. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554
28. Holmes CL, Russell JA, Walley KR. Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest 2003;124:1103-1115
29. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000;405:847-856
30. Zhang S, Sha Q, Chen HS, Dong J, Jiang R. Transmission/disequilibrium test based on haplotype sharing for tightly linked markers. Am J Hum Genet 2003;73:566-579
31. Iles MM. Linkage and association: the transmission/disequilibrium test for QTLs. Methods Mol Biol 2002; 195:101-138
32. Lee WC. Transmission/disequilibrium test when neither parent is available in some families: a noniterative approach. J Cancer Epidemiol Prev 2002;7:97-103
33. Devlin B, Roeder K, Wasserman L. Genomic control, a new approach to genetic-based association studies. Theor Popul Biol 2001;60:155-166
34. Bacanu SA, Devlin B, Roeder K. The power of genomic control. Am J Hum Genet 2000;66:1933-1944
35. Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis 2002;23:381-387
36. Lynch M, Walsh B. Genotype X environment interactions. In Genetics and Analysis of Quantitative T traits. Sunderland, MA: Sinauer Associates; 1998:657-685
37. Wood KA, Angus DC. Reducing variation and standardizing practice: the key to better ICU care? Curr Opin Crit Care 2001;7:281-283
38. Wood KA, Huang D, Angus DC. Improving clinical trial design in acute lung injury. Crit Care Med 2003;31:S305-S311
39. Cooper R, Rotimi C, Ataman S, et al. The prevalence of hypertension in seven populations of west African origin. Am J Public Health 1997;87:160-168
40. Hendrie HC, Ogunniyi A, Hall KS, et al. Incidence of dementia and Alzheimer disease in two communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA 2001;285:739-747
41. Cooper RS. Gene-environment interactions and the etiology of common complex disease. Ann Intern Med 2003;139:437-440
42. Huang Q, Liu D, Majewski P, et al. The plasticity of dendritic cell responses to pathogens and their components. Science 2001;294:870-875
43. Pinsky MR. Genetic testing: costs and access to intensive care unit care. Crit Care Med 2003;31:S411-S415